Case Study: SNIPR Biome achieves faster, more efficient CRISPR-based therapeutic development with Benchling

Pioneering CRISPR-based microbial gene therapy with a modern, scalable R&D platform

SNIPR Biome is a clinical‑stage biopharma company developing CRISPR‑based microbial gene therapies—using both precision CRISPR killing (with lead candidate SNIPR001 in clinical trials) and engineered bacteria that deliver therapeutic payloads in the gut. Early growth revealed R&D pain points: fragmented data across spreadsheets and point solutions, poor bio‑aware data capture, and slowed program velocity that risked missing experimental opportunities and delaying milestones.

By adopting Benchling as a standardized, bio‑aware R&D platform, SNIPR centralized templates, experiment records, and molecular inventories, reduced manual entry and third‑party tool use, and improved traceability and team handoffs. The result: faster, more efficient science and IT workflows, higher confidence in advancing promising candidates, accelerated milestone progress (including a $50M Series A and extended collaboration with Novo Nordisk), and stronger IP documentation to support clinical development.

SNIPR Biome

Ana de Santiago Torio

Team Lead Laboratory Management